|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
|---|---|
| Information provided by: | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
| ClinicalTrials.gov Identifier: | NCT00566592 |
Purpose
Hypoglycemia is the principal barrier to the achievement of target glycemic goals in type 2 diabetes. Alcohol consumption is very prevalent in our society and a proven cause of hypoglycemia. Population studies suggest that elderly, insulin requiring type 2 diabetes patients are particularly vulnerable to severe hypoglycemia and that this problem accounts for an estimated $50 million or more in healthcare costs in the USA each year. We hypothesize that low dose ethanol significantly increases the vulnerability to overnight hypoglycemia and impairs the recovery of plasma glucose in elderly, insulin requiring patients with type 2 diabetes. Our preliminary studies suggest that low dose ethanol impairs recovery from day time insulin-induced hypoglycemia in type 2 diabetes patients but not in age matched healthy control subjects. The proposed studies will examine the effects of low dose ethanol on overnight glucose regulation in elderly, insulin requiring type 2 diabetes patients and will establish the mechanism of these impairments through a series of systematic evaluations. Specifically, these studies will document suppression of the dawn phenomenon by ethanol, and/or exacerbation of a deficient counterregulatory response to hypoglycemia during sleep, especially growth hormone. Specific mechanisms for the suppression of growth hormone to be examined include that evening ethanol (3) inhibits peak overnight ghrelin secretion and/or (4) reduces pituitary sensitivity to GHRH. Additionally, these studies will characterize (5) the dose response characteristics of ethanol on overnight glucose homeostasis and will (6) carefully evaluate the effect of the timing of ethanol administration in relation to meal ingestion on overnight hypoglycemic vulnerability. To address these aims, we will assess the effect of moderate doses of orally administered ethanol or placebo on overnight growth hormone release, ghrelin, total IGF-1, free IGF-1, insulin-like growth factor binding protein 1 (IGFBP-1) concentrations, glucose production and other parameters of glucose homeostasis among elderly control subjects versus elderly, insulin requiring subjects with type 2 diabetes. These important studies will provide a scientific basis for the prevention of overnight hypoglycemia (and the attendant cost savings) by providing mechanistic insights into the causes of nocturnal hypoglycemia.
| Condition | Intervention |
|---|---|
|
Type 2 Diabetes, Insulin Requiring |
Other: oral ethanol, overnight Other: IV ethanol Other: soda water |
| Study Type: | Interventional |
| Study Design: | Randomized, Single Blind (Subject), Crossover Assignment |
| Official Title: | The Effect of Ethanol on Overnight Glucose Regulation in Type 2 Diabetes Mellitus |
| Estimated Enrollment: | 24 |
| Study Start Date: | January 2005 |
| Estimated Study Completion Date: | December 2009 |
| Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
1: Experimental
Oral ethanol, overnight
|
Other: oral ethanol, overnight
Oral ethanol before bedtime to achieve approximate BAL of 0.08%
|
|
2: Experimental
IV ethanol, overnight
|
Other: IV ethanol
IV ethanol before bedtime to achieve approximate BAL of 0.08%
|
|
3: Placebo Comparator
Placebo, overnight
|
Other: soda water
Oral Placebo before bedtime to achieve approximate BAL of 0.00%
|
|
4: Placebo Comparator
Placebo, daytime
|
Other: soda water
Oral Placebo to achieve approximate daytime BAL of 0.00%
|
Eligibility| Ages Eligible for Study: | 50 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria: All type 2 diabetes subjects will be aged 50 to 75 years and will have carried the diagnosis of diabetes according to standard criteria and will be receiving insulin therapy alone or in combination with oral diabetes medications for at least 6 months. To exclude subjects with type 1 diabetes, all patients will be anti-GAD antibody negative and will retain the ability to secrete some nominal level of c-peptide in response to stimulation (i.e.- at least 2 ng/ml after ingesting Boost Plus). All subjects will be mentally fit to give informed consent. Nondiabetic control subjects will meet similar inclusion criteria (except for diabetes and hemoglobin A1C criteria). Control subjects will be matched as a group for age, gender and BMI. Finally, control subjects will undergo a standard 75 gram Oral Glucose Tolerance Test to assure the presence of normal glucose tolerance (142).
Exclusion Criteria: Exclusion criteria for all study subjects will include the existence of severe cardiovascular, hepatic or renal disease, or current malignancy as determined by the screening evaluation. Subjects with a past or current history of drug or alcohol abuse will also be excluded from study, as will subjects with a previously diagnosed seizure disorder, subjects with sleep apnea by medical history or as demonstrated during the accommodation sleep study night, subjects with diabetic gastroparesis, or subjects receiving current treatment medications that interfere with glucose homeostasis other than for diabetes therapy (e.g.- glucocorticoids, orlistat). Because of the known adverse effects of ethanol on unborn children, current intrauterine pregnancy will exclude patients from study. A body mass index greater than 36 kg/m2 will also be exclusionary. Additionally, subjects with a score of more than eight points on the Alcohol Use Disorders Identification Test (AUDIT) will be excluded from study.
Contacts and Locations| Contact: Mark R Burge, MD | 5052724658 | mburge@salud.unm.edu |
| United States, New Mexico | |
| University of New Mexico Clincal and Translational Science Center | Recruiting |
| Albuquerque, New Mexico, United States, 87131 | |
| Contact: Monica Thompson, MA 505-272-0195 monthompson@salud.unm.edu | |
| Principal Investigator: Mark R Burge, MD | |
| Principal Investigator: | Mark R Burge, MD | University of New Mexico |
More Information
| Responsible Party: | University of New Mexico ( Mark R. Burge, MD ) |
| Study ID Numbers: | DK61990, DK061990 |
| Study First Received: | November 29, 2007 |
| Last Updated: | November 5, 2008 |
| ClinicalTrials.gov Identifier: | NCT00566592 |
| Health Authority: | United States: Federal Government |
|
Metabolic Diseases Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases |
Endocrinopathy Metabolic disorder Glucose Metabolism Disorders Ethanol |
|
Anti-Infective Agents Anti-Infective Agents, Local Therapeutic Uses Physiological Effects of Drugs |
Central Nervous System Depressants Central Nervous System Agents Pharmacologic Actions |
